‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales
Executive Summary
Regeneron and Sanofi have opportunity to appeal or to reach resolution with Amgen after district judge delays imposition of permanent injunction for 30 days in PCSK9 patent case.
You may also be interested in...
PCSK9 Patent Battle: Amgen Seeks Supreme Court Review Ahead Of February Trial
Amgen opposes US Federal Circuit's standard for determining adequacy of an invention's written description, which led court to overturn jury verdict that its Repatha patents are valid.
Hemlibra Patent Dispute Spills Over Into Patient Community
After Shire seeks preliminary injunction to carve-out certain patients from obtaining the hemophilia treatment, Genentech issues open letter saying patients should not be put in the middle of a patent dispute.
PCSK9 Patent Case: Praluent Injunction Vacated, But May Well Return
Appeals court vacates injunction that Repatha marketer Amgen had won against Sanofi/Regeneron's Praluent, but notes 'a reduction in choice of drugs cannot be the sole reason for a district court to deny an injunction.'